Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCX10013 in Paroxysmal Nocturnal Hemoglobinuria
NCT06100900Phase 1Completed
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of BCX10013 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Number of Participants with Treatment-Emergent Adverse Events and Graded Laboratory Abnormalities up to 52 weeks. Started Oct 2023; status: completed.
02
Drugs
BCX10013
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06100900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06100900.